Welcome to our dedicated page for Shoulder Innovations SEC filings (Ticker: SI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Shoulder Innovations, Inc. (NYSE: SI) provide detailed regulatory information about the company’s operations as a commercial-stage medical technology business focused on shoulder surgical care. These documents include current reports on Form 8-K that describe material events such as quarterly financial results and key corporate announcements.
Recent Forms 8-K furnished by Shoulder Innovations cover financial results for quarters ended June 30 and September 30, 2025. In these filings, the company provides net revenue, gross margin, operating loss, net loss and related financial data, along with discussions of factors affecting performance. The filings also reference non-GAAP measures such as Adjusted EBITDA and explain how these metrics are calculated and their limitations.
Other 8-K filings document significant corporate developments. For example, the company has furnished press releases announcing its initial public offering and convertible notes financing, as well as a strategic partnership with Interventional Systems to introduce a shoulder-specific micro-robotic solution that is expected to integrate with the ProVoyance platform. These filings help investors track how Shoulder Innovations is expanding its ecosystem of advanced implant systems, enabling technologies and instrument systems for shoulder arthroplasty.
On Stock Titan’s SEC filings page, users can access these reports as they are made available through the EDGAR system. AI-powered tools can assist in summarizing lengthy filings, highlighting items such as revenue trends, operating results, non-GAAP reconciliations and descriptions of material agreements or partnerships. Users can also review filing exhibits, including earnings press releases and, where provided, conference call transcripts furnished as exhibits to Form 8-K.
Together, the SEC filings for SI offer a structured view of Shoulder Innovations’ financial reporting, regulatory disclosures and significant events related to its focus on the shoulder surgical care market.
Shoulder Innovations (SI) filed an 8‑K reporting its quarterly results disclosure. The company announced that it issued a press release with financial results for the quarter ended September 30, 2025 and hosted a conference call on November 11, 2025 to discuss those results and full‑year 2025 guidance.
The press release is furnished as Exhibit 99.1 and the call transcript as Exhibit 99.2. The materials are being furnished, not filed, under the Exchange Act and are not subject to Section 18 liabilities, nor incorporated by reference unless specifically referenced.
Jeffrey S. Points, Chief Financial Officer of Shoulder Innovations, Inc. (SI), reported multiple transactions in September 2025. On 09/11/2025 he was reported as acquiring 13,264 shares (transaction code M) at a price of $2.4804 and a stock option covering 13,264 underlying shares with the same $2.4804 exercise price expiring 11/16/2033. On 09/12/2025 he acquired an additional 1,600 shares at $15.67. After these transactions he beneficially owned 52,445 shares directly and had 50 shares indirectly held by his son. The option vests in 31 equal monthly increments starting March 31, 2025.
Shoulder Innovations, Inc. (SI) Form 4 shows insider David Lawrence Blue, identified as Chief Customer Experience Officer, reported transactions dated 09/12/2025. The filing records two non-derivative acquisitions and corresponding derivative option entries: 78,616 shares acquired at an effective price of $2.0988 and 15,778 shares acquired at $2.4804.
Following these transactions the reporting person beneficially owned 138,331 shares in total. The filing notes the first option is fully vested and exercisable and the second option vests partly (one-fourth on 04/19/2024) with the remainder vesting monthly through May 2033. The form was signed by an attorney-in-fact on 09/15/2025.
Robert Joseph Ball, CEO, Executive Chairman and a director of Shoulder Innovations, Inc. (SI), reported open-market purchases of the company's common stock on two dates in September 2025. On 09/11/2025 he acquired 2,000 shares at a weighted-average price of $14.9048, bringing his direct holdings to 105,259 shares. On 09/12/2025 he acquired 6,000 shares at a weighted-average price of $15.4909, increasing his direct holdings to 111,259 shares.
The filing states the prices are weighted averages from multiple transactions with specified price ranges and was signed by an attorney-in-fact on 09/15/2025. No derivative transactions, disposals, or other material events are reported in this Form 4.
Matthew Fraser Ahearn, Chief Operating Officer and Director of Shoulder Innovations, Inc. (SI), reported option and related common stock transactions dated 09/11/2025. The filing shows acquisitions of three option tranches exercisable into common stock: 12,286 options at a $0.9349 exercise price, 78,616 options at $2.0988, and 16,443 options at $2.4804. Following these reported transactions, the filing records beneficial ownership rising to 215,379 common shares (direct). The first option tranche is fully vested and exercisable; the third tranche vests one-fourth on April 19, 2024 and the remainder in 36 monthly increments. The form is signed by an attorney-in-fact on 09/15/2025.
Shoulder Innovations, Inc. is a commercial-stage medical device company focused on shoulder arthroplasty. The company completed a Series E preferred financing in 2025 with gross commitments of $40,130 thousand and recognized a $11,719 thousand change in fair value related to the Series E purchase option for the six months ended June 30, 2025. It completed an IPO on August 1, 2025, selling 5,000,000 shares at $15.00 and receiving approximately $64,800 thousand net proceeds. As of June 30, 2025, cash, cash equivalents and marketable securities totaled $39,635 thousand. The company had an accumulated deficit of $80,899 thousand and expects continued losses while scaling commercialization, R&D and regulatory efforts. It amended a loan facility and remains in compliance with covenants. The filing discloses litigation, product liability and regulatory risks and a 1-for-19.08 reverse stock split in July 2025.
Shoulder Innovations, Inc. filed a current report to share that it has released its financial results for the quarter ended June 30, 2025. On September 9, 2025, the company issued a press release with these results, which is furnished as Exhibit 99.1.
The company notes that the press release and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
FMR LLC and Abigail P. Johnson report beneficial ownership of 3,848,791 shares of Shoulder Innovations Inc. common stock, representing 19.0% of the class. The filing shows FMR LLC has 3,830,491 shares with sole voting power and 3,848,791 shares with sole dispositive power; Abigail P. Johnson is reported with sole dispositive power for the same aggregate amount and no voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. An exhibit is referenced for a 13d-1(k) agreement and powers of attorney are referenced by prior filings.